Eli Lilly (LLY) and Astellas Pharma have entered into two separate asset sale agreements with Sangamo Therapeutics as part of Sangamo's voluntary Chapter 11 reorganization, the genomic medicine company said Tuesday.
Lilly's agreement covers Sangamo's capsid delivery platform, zinc finger platform, modular integrase platform and the prion disease program ST-506, while Astellas' agreement involves the the Fabry disease program ST-920, Sangamo said.
Lilly and Astellas will serve as "stalking horse" bidders in a court-supervised auction process, Sangamo said.
Sangamo said it has secured commitment for debtor-in-possession financing to support ongoing operations.
The petition was filed in the US Bankruptcy Court for the District of Delaware.
Price: $1107.53, Change: $+3.50, Percent Change: +0.32%